KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Jazz Pharmaceuticals (JAZZ) Asset Writedowns and Impairment (2018 - 2023)

Jazz Pharmaceuticals has reported Asset Writedowns and Impairment over the past 6 years, most recently at $61.0 million for Q4 2023.

For Q4 2023, Asset Writedowns and Impairment changed N/A year-over-year to $61.0 million; the TTM value through Dec 2023 reached $194.7 million, up 45.65%, while the annual FY2023 figure was $61.0 million, 54.35% down from the prior year.
Asset Writedowns and Impairment for Q4 2023 was $61.0 million at Jazz Pharmaceuticals, down from $133.6 million in the prior quarter.
Over five years, Asset Writedowns and Impairment peaked at $136.1 million in Q1 2020 and troughed at $61.0 million in Q4 2023.
A 3-year average of $110.3 million and a median of $133.6 million in 2022 define the central range for Asset Writedowns and Impairment.